Sangamo and Novartis Enter Agreement to Focus on Neurodevelopmental Diseases

Genomic medicine company Sangamo Therapeutics announced today that it has entered a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies for three neurodevelopmental targets, including autism spectrum disorder.